Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE.
Chrisanthar R, et al. Among authors: aas t.
PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249.
PLoS One. 2011.
PMID: 21556366
Free PMC article.
Clinical Trial.